The Rho activator ECT2 functions as a key regulator in cytokinesis. ECT2 is phosphorylated during G2/M phase, but the physiological significance of this event is not well known. In this study, we show that phosphorylation of ECT2 at threonine-341 (T341) affects the autoregulatory mechanism of ECT2. In G2/M phase, ECT2 was phosphorylated at T341 most likely by Cyclin B/Cyclindependent kinase 1 (Cdk1), and then dephosphorylated before cytokinesis. Depletion of ECT2 by RNA interference (RNAi) efficiently induced multinucleate cells. Expression of the phospho-deficient mutant of ECT2 at T341 suppressed the multinucleation induced by RNAi to ECT2, indicating that ECT2 is biologically active even when it is not phosphorylated at T341. However, the phospho-mimic mutation at T341 weakly stimulates the catalytic activity of ECT2 as detected by serum response element reporter gene assays. As T341 is located at the hinge region of the N-terminal regulatory domain and C-terminal catalytic domain, phosphorylation of T341 may help accessing downstream signaling molecules to further activate ECT2. We found that the phospho-mimic mutation T341D increases binding with itself or the N-terminal half of ECT2. These results suggest a conformational change of ECT2 upon phosphorylation at T341. Therefore, ECT2 activity might be regulated by the phosphorylation status of T341. We propose that T341 phosphorylation by Cyclin B/Cdk1 could be a trigger for further activation of ECT2.
Introduction
ECT2 associates with a subset of Rho GTPases (Miki et al., 1993) , and functions as a guanine nucleotide exchange factor (GEF) for RhoA, Rac1, and Cdc42 (Tatsumoto et al., 1999) . Structurally, ECT2 contains two tandem BRCA1 C-terminal (BRCT) repeats (the BRCT domains) at the N-terminal half. The C-terminal half contains the RhoGEF motif, which consists of the Dbl homology (DH) and pleckstrin homology (PH) domains. Unlike other known GEFs, ECT2 exhibits nuclear localization in interphase, disperses throughout the cytoplasm in prometaphase, and then accumulates in the midbody during cytokinesis. Expression of a dominant-negative form of ECT2, microinjection of anti-ECT2 antibody, or knockdown of ECT2 by small interfering RNA (siRNA) inhibits cytokinesis, resulting in multinucleated cells (Tatsumoto et al., 1999; Liu et al., 2004) . Expression of dominant negative ECT2 suppresses the activation of RhoA during cytokinesis (Kimura et al., 2000; Yoshizaki et al., 2004) . While ECT2 is a critical regulator for cytokinesis, it is not well known exactly how ECT2 is regulated during this process.
Phosphorylation of ECT2 seems to be one of the regulatory mechanisms of ECT2. We previously reported that ECT2 is phosphorylated during G2 and M phases (Tatsumoto et al., 1999) . However, it is still unclear how ECT2 phosphorylation affects cytokinesis. Phosphorylation of ECT2 is required for its exchange activity (Tatsumoto et al., 1999) . On the other hand, it has been shown that Cyclin B and B3 genetically inhibit the function of pebble, the Drosophila ortholog of ECT2 (Echard and O'Farrell, 2003) , implying a relationship between pebble and the Cyclin B/Cyclin-dependent kinase 1 (Cdk1) complex. Cyclin B/Cdk1 phosphorylates various proteins during mitosis. The targets of Cyclin B/Cdk1 include both structural proteins involved in the execution of mitotic events and regulatory proteins that are necessary for the control and timing of mitotic events (Obaya and Sedivy, 2002) . Moreover, Cdk1 inactivation is required for the onset of cytokinesis (Wheatley et al., 1997; O'Keefe et al., 2001) . The timing of cytokinesis, at least in part, is determined by the localization of MKLP1 on the central spindle (Mishima et al., 2004) . Cdk1 phosphorylates MKLP1 to inhibit the localization of MKLP1 to the central spindle. Thus, Cdk1 may also regulate ECT2 in conjugation with the determination of the timing of cytokinesis.
In this report, we show that ECT2 is phosphorylated at threonine-341 (T341) during G2/M phase. We analysed the effect of phosphorylation at T341 of ECT2. Our results reveal that this phosphorylation of ECT2 caused a change in the conformation of the ECT2 molecule. Thus, ECT2 activity may be regulated by T341 phosphorylation during mitosis.
Results
ECT2 is phosphorylated at T341 during mitosis ECT2 is phosphorylated during G2/M phase (Tatsumoto et al., 1999; Kimura et al., 2000) . Our initial attempt to purify ECT2 from mitotic cells and determine the phosphorylation sites by mass spectrometry analyses was not successful (data not shown). As an alternative approach, we chose to test in vitro phosphorylation of ECT2 by mitotic kinases. We focused on Cdk1 and Plk1 as candidate kinases. Cdk1 is a proline-directed kinase and recognizes serine-proline or threonine-proline sites (S/T-P sites) Ubersax et al., 2003) . We found twelve S/T-P sites in human ECT2 (i.e. Ser ). It has been reported that the polo-box domain of Plk1 recognizes the S-(pS/pT)-P motif, which has been phosphorylated by Cdk1 (Thiel et al., 2002; Elia et al., 2003) . Thus, Cdk may facilitate subsequent Plk1-dependent phosphorylation, and threonine (T)412, which is proceeded by serine, could be such a Plk1 recognition site. To identify the phosphorylation sites of ECT2, bacterially expressed GST-ECT2 was phosphorylated sequentially with Cyclin B/Cdk1 and Plk1, and subjected to mass spectrometry analysis. These analyses revealed that GST-ECT2 was phosphorylated at serine (S)-20, S245, T341, and T400 in vitro (Table 1) . Among them, T341 and T400 were followed by proline and therefore considered Cdk1-phosphorylation sites.
As the monoclonal anti-phospho TP (pTP) antibody recognizes the phosphorylated TP sequence (Lowery et al., 2004; Mishima et al., 2004) , we tested whether it detects ECT2. Endogenous ECT2 was detected by antipTP antibody in ECT2 immunoprecipitates from mitotic cells, but not from interphase cells (Figure 1a , middle). The gel mobility of ECT2 from mitotic cells was slightly retarded under these conditions (Figure 1a , left). We have previously shown that this band shift is attributed to ECT2 phosphorylation (Tatsumoto et al., 1999) . Thus, ECT2 was phosphorylated at TP site(s) during mitosis.
To test whether T341 is phosphorylated in vivo, we raised phospho-specific antibodies against this site. Like anti-pTP antibody, anti-phospho-T341 antibody (antipT341) recognized ECT2 immunoprecipitated from cells in M phase, but not ECT2 from cells in G1/S phase (Figure 1a, right) .
To examine phosphorylation at T341 in detail, we created a phospho-deficient mutant at this site of ECT2 (T341A), in which T341 has been replaced by alanine 
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In vitro phosphorylation sites of ECT2 were determined by nanoelectrospray tandem mass spectrometry as described under 'Materials and methods'. Definitive phosphorylation sites are indicated with asterisks. (A). We transiently expressed green fluorescence protein (GFP), GFP-tagged wild-type ECT2 (WT-ECT2, full length), or its T341A mutant in HeLa cells (Figure 1b ). Cells were arrested by nocodazole and ECT2 was immunoprecipitated by anti-ECT2 antibody. Whereas endogenous ECT2 and exogenously expressed WT-ECT2 were detected either by anti-T341 or anti-pTP antibody in the immunoprecipitates from cells at M phase, introduction of a phospho-deficient mutation at T341 diminished the signal displayed by these antibodies (Figure 1b ). These data indicated that T341 of ECT2 was phosphorylated during mitosis in vivo. In addition, anti-pT341 antibody specifically recognized the phosphorylation at T341 of ECT2 in the immunoprecipitates by anti-ECT2 antibody.
To confirm whether T341 can be phosphorylated by Cyclin B/Cdk1, we carried out in vitro kinase assays (Figure 2a ). GFP-tagged WT-ECT2 or its phosphodeficient mutant was transiently expressed in HEK 293T cells, immunoprecipitated with anti-ECT2 antibody, and incubated with Cyclin B/Cdk1. WT-ECT2 incubated with Cyclin B/Cdk1 was detected by anti-pT341 antibody as well as anti-pTP antibody. In contrast, the T341A mutant incubated with Cyclin B/Cdk1 was barely detectable by either anti-pT341 or anti-pTP antibody. Reduction of the signal by either anti-pT341 or anti-pTP antibody in T341A mutant indicated that T341 is a major phosphorylation site in vitro. These results suggested that T341 is phosphorylated by Cyclin B/Cdk1 in vitro.
To test whether Cdk1 phosphorylates T341 in vivo, HeLa cells were arrested with nocodazole, and then treated with the Cdk inhibitor roscovitine (Meijer et al., 1997; Obaya and Sedivy, 2002) . Roscovitine effectively diminished the signal displayed by anti-pT341 or antipTP antibody, while it did not affect the expression level of ECT2 (Figure 2b ). Thus, T341 appears to be phosphorylated by Cdk in vivo. As T341 phosphoryla- Figure 2 Phosphorylation of ECT2 at T341 by Cyclin B/Cdk1 in vitro and in vivo. (a) GFP vector and ECT2 derivatives were transfected into cultured HEK 293T. Cells were grown under normal conditions and lysed 24 h after transfection. ECT2 was immunoprecipitated using anti-ECT2 antibody. The precipitates were incubated with Cyclin B/Cdk1. The samples were separated by SDS-PAGE and analysed by immunoblotting using anti-pT341, anti-pTP, and anti-ECT2 antibodies. Panels show the signal of exogenously expressed ECT2. The faint signal in WT-ECT2 treated without Cyclin B/Cdk1 was due to the phosphorylation of ECT2 in cultured cells before in vitro kinase reaction and this background was not observed in the T341A mutant. Endogenous ECT2 was not detectable by anti-pT341 antibody under these conditions. (b) HeLa cells were treated with nocodazole for 12 h, followed by vehicle (DMSO) alone or roscovitine for 30 min. As a control, HeLa cells cultured without synchronization were also prepared. ECT2 was immunoprecipitated and analysed by immunoblotting with anti-pT341, anti-pTP, and anti-ECT2 antibodies. tion occurred at G2/M phase, T341 was phosphorylated most likely by Cdk1. We have previously shown that G2/M phosphorylation of ECT2 results in a mobility shift ( Figure 1a ; Tatsumoto et al., 1999) . This alteration of the gel mobility of ECT2 induced by nocodazole treatment was also restored by roscovitine treatment (Figure 2b , lane 3), suggesting that the Cdk1-related events are responsible for the gel mobility change of ECT2 in M phase.
We also analysed the phosphorylation status of T341 after nocodazole release. When cells arrested at prometaphase by nocodazole treatment (Figure 3a , 0 min) were released to normal culture conditions, most of the cells entered the cytokinesis stage within 90 min of the release (Figure 3a , 90 min). Phosphorylation of ECT2 at T341 dramatically decreased at this point and was not detectable 180 min after release from nocodazole ( Figure 3b ). At this time point, most of the cells had entered G1, although a minor fraction persisted in cytokinesis ( Figure 3a and b, 180 min), suggesting that ECT2 is dephosphorylated at T341 before cytokinesis.
Thus, dephosphorylation of ECT2 at T341 was coincident with inactivation of Cyclin B/Cdk1 at mitotic exit.
Subcelluar localization of WT-ECT2 and T341 mutants T341 is located close to one of the nuclear localization signals (see Figure 9b ). To investigate the effects of phosphorylation of ECT2 at T341 on its subcellular localization, we constructed a phospho-mimic mutant (T341D) of ECT2, in which T341 had been replaced by asparatic acid (D). We examined the subcellular localization of GFP-tagged WT-ECT2 and its T341 mutants in HeLa cells. Exogenously expressed WT-ECT2 showed a similar localization as endogenous ECT2 in HeLa cells (data not shown). The introduction of the phospho-deficient or phospho-mimic mutation at T341 to ECT2 did not significantly affect the subcellular localization compared to WT-ECT2 ( Figure 4 ). These observations suggested that the phosphorylation at T341 did not appear to be responsible for ECT2 localization during cell division. The sense strand sequence of siRNA duplexes (ECT2 nucleotides, 638-658) is shown by bold letters. Amino acids estimated from the cDNA sequence are shown at the top. Mutations at six locations (underlines) were introduced in the siRNAresistance ECT2 expression vector, leaving the amino-acid sequence unchanged. (b) ECT2 or control-siRNA was transfected into HEK 293T cells. The expression level of endogenous ECT2 was analysed by immunoblotting with anti-ECT2 antibody 48 h after transfection. (c) GFP vector, GFP-tagged WT-ECT2, or siRNA-resistant version of ECT2 derivatives (WT-ECT2-R, T341A-R, and T341D-R) were cotransfected with ECT2 siRNA into HEK 293T cells. GFP-WT-ECT2 was also expressed in HEK 293T in the absence of ECT2 siRNA. The expression level of ECT2 derivatives was analysed by immunoblotting with anti-ECT2 antibody 48 h after transfection. (d) GFP-tagged ECT2 derivatives were observed by fluorescence microscopy in the presence of ECT2 siRNA 24 h after transfection. Bar, 20 mm. (e) Some of transfectants were transferred to a collagen-coated glass slide 48 h after transfection. Cells were fixed with 4% PFA 24 h after transfer. The percentages of multinucleated cells were determined using fluorescence microscopy, and the ratio of multinucleated cells was calculated. The averages of six experiments are shown. The number of total observed GFPexpressing cells (n) was as follows: Single transfection: No treatment (n ¼ 603), Control siRNA (n ¼ 638), ECT2 siRNA (n ¼ 1153). Cotransfection with control siRNA:
T341 phosphorylation is not required for the biological activity Since ECT2 is involved in cytokinesis, we focused on the effect of T341 mutants on this process. We first tested whether multinucleated cells could be induced by expression of ECT2 derivatives in HEK 293T cells, because the requirements of the Rho-mediated pathway for cytokinesis are diverse among cultured cell lines Mitotic phosphorylation of ECT2 T Hara et al (Yoshizaki et al., 2004) . Expression of the N-terminal half of ECT2 (ECT2-N, amino acids 1-333) exhibits the dominant-negative phenotype in HeLa and U2OS cells, resulting in a generation of multinucleated cells (Tatsumoto et al., 1999; Matuliene and Kuriyama, 2004) . We found that the dominant-negative effect of ECT2-N is also observed in HEK 293T cells ( Figure 5 ). The DH domain mutant of ECT2 (DH mutant) lacks the transforming activity in NIH 3T3 cells (Saito et al., 2004) . Expression of the DH mutant, whose GEF activity was impaired (see Figure 7b ) and therefore expected to exhibit a dominant-negative effect, also induced multinucleated cells (Figure 5b) . However, the effect of the DH mutant on multinucleated cell formation was not as dramatic as that of ECT2-N (Figure 5b ). This observation suggested that the high efficiency of ECT2-N to inhibit cytokinesis is not solely due to the lack of its catalytic activity. For example, cytoplasmic localization of ECT2-N stimulates multinucleate cell formation (Saito et al., 2003) .
We found that overexpression of WT-ECT2 also led to a generation of multinucleated cells in HEK 293T ( Figure 5 ). Interestingly, WT-ECT2 transfectants specifically exhibited cells with micronuclei (Figure 5a ), although the frequency of micronuclei formation was less than 5% of multinucleated cells. Such micronuclei formation was not observed in ECT2-N-or DH mutantexpressing cells (data not shown). Besides this morphology, the cell shape became round in 20-30% of multinucleated cells induced by WT-ECT2 expression (Figure 5a ). Expression of either the phospho-mimic or phospho-deficient mutant of T341 also led to multinucleated cells (Figure 5b ), a minor fraction of which exhibited the micronucleated and rounded phenotypes (data not shown). These results suggest that the phenotype of T341D is more similar to WT-ECT2 rather than its DH mutant. In addition, expression of the phospho-mimic mutant induced multinucleated cells more efficiently than WT-ECT2. In contrast, T341A mutant displayed a phenotype very similar to that of WT-ECT2 (Figure 4b ). Taken together, these results suggested that T341 phosphorylation is not required for the biological activity of ECT2.
Expression of T341 mutants restores normal cytokinesis in ECT2 siRNA-transfected cells To further examine whether T341 mutants are biologically active, we replaced endogenous ECT2 by the T341 mutants using RNA interference (RNAi) rescue assays. First, endogenous ECT2 was depleted by ECT2 siRNA (Figure 6a ). The number of multinucleated cells increased in the cells treated with ECT2 siRNA, but not with control siRNA, in HEK 293T cells (see Figure 6e , left). Thus, siRNA of ECT2 was effective in HEK 293T cells. To express mutant ECT2 in these cells, we constructed siRNA-resistant ECT2 expression vectors (Figure 6b ). The siRNA-resistant ECT2 derivatives were cotransfected with ECT2 siRNA to HEK 293T cells, and their expression levels were analysed by immunoblotting (Figure 6c ) and fluorescence microscopy ( Figure 6d ). The siRNA-resistant ECT2 derivatives were expressed in the presence of siRNA to ECT2, whereas the expression of WT-ECT2 (siRNAsensitive) was not observed despite its higher expression in the absence of ECT2 siRNA (Figure 6c ). Endogenous ECT2 was not detectable under these conditions.
We scored multinucleated cells in these transfectants (Figure 6e ). When siRNA of ECT2 was cotransfected with each ECT2 derivative, the multinucleated phenotype induced by ECT2 siRNA was rescued by expression of the T341A-R mutant as well as WT-ECT2-R (Figure 6e, right) . In contrast, the GFP vector did not rescue the phenotype. The expression of the phosphomimic mutant T341D-R also decreased the level of multinucleation induced by ECT2 RNAi. These results suggested that both phospho-mimic and phosphodeficient mutants are biologically active. Since the high expression level of ECT2 derivatives induced multinucleated cells (see Figure 5 ) and might yield high background for siRNA rescue experiments, we attempted to use a smaller amount of the plasmid DNA compared to the previous experiments. However, expression of siRNA-resistant ECT2 derivatives still induced multinucleated cells when the control siRNA was cotransfected (Figure 6e, middle) . Thus expression of the mutant ECT2 in addition to endogenous ECT2 might induce multinucleate cells. These results also suggest that these ECT2 mutants are biologically active. Consistent with the previous results ( Figure 5 ), expression of the T341D-R mutant led to multinucleated cell formation more efficiently than WT-ECT2-R under these conditions (Figure 6e , middle).
Phospho-mimic mutation at T341 marginally enhances ECT2 activity Since T341 mutations did not affect the localization of ECT2 (Figure 5 ), stronger effect of the T341D mutant on multinucleation (Figures 5b and 6e middle) might indicate higher catalytic activity. To test this possibility, we examined whether the phosphorylation of T341 led to a change in the activity of ECT2. While straightforward assays of ECT2 activity are not available, we found that ECT2 overexpression results in an increased cytoplasmic localization, leading to Rho activation (Saito et al., 2004) . To measure the activity in vivo, we performed an serum response element (SRE) reporter gene assay that relies on the ability of Rho to activate transcription of reporter genes fused to the SRE promoter element (Hill et al., 1995) . SRE-regulated transcriptional activation by ECT2 in NIH3T3 cells has been reported previously (Saito et al., 2004) . To increase sensitivity to the effects of ECT2, we used HEK 293T cells. First, we tested whether this assay is quantitative. Relative luciferase activity was correlated with the amount of DNA with linearity between 0.25 and 2 mg DNA of WT-ECT2 (Figure 7a ). The relative luciferase activity of the DH mutant-transfected cells was similar to that of GFP-expressing cells and nontransfectants (data not shown). The phospho-mimic mutant T341D exhibited a higher activity than WT-ECT2, while the phospho-deficient mutation did not significantly affect the activity (Figure 7b ). The expression level of ECT2 derivatives was comparable (Figure 7c ). These results suggest that although the phosphorylation of ECT2 at T341 is not required for its catalytic activity, it significantly enhances the activity.
T341 is important for the conformational change of ECT2
The catalytic activity of ECT2 is regulated by the intramolecular interaction between the N-terminal half and DH domain (Saito et al., 2004) . T341 is located at the small central domain (S domain) that is placed between the BRCT and DH domains (Saito et al., 2003) . The S domain appeared to be a hinge region of the ECT2 molecule, which plays a role in regulation of the catalytic activity. Although the phospho-deficient mutation at T341 did not inhibit the activity, the phosphomimic mutation significantly enhanced the activity (Figure 7) . Therefore, we assumed that phosphorylation of T341 might increase the catalytic activity by inducing a conformational change in the ECT2 molecule. To test this idea, we examined the binding affinity of T341 mutants with ECT2-N and compared it to that of WT-ECT2 (Figure 8a ). When ECT2 is in a closed structure, additional ECT2-N, which is expressed as a Flag-tagged molecule, cannot access the DH domain of ECT2, whereas it can associate with ECT2 of an open structure. Consistent with the previous report (Saito et al., 2004) , ECT2-N interacted with ECT2-C (amino acids 414-882) as well as WT-ECT2. If phosphorylation at T341 induced a conformational change that relieves interaction between the DH domain and N-terminal ECT2, ECT2 molecules would have an open structure. In this case, an additional ECT2-N could interact with ECT2 more freely. Consistent with this expectation, we found that the phospho-mimic mutant increased its binding with ECT2-N compared to that with WT-ECT2, whereas the phospho-deficient mutant did not increase the interaction of ECT2-N (Figure 8a ). These data strongly suggest that the structure of ECT2 opens when T341 is phosphorylated. We also tested the interaction of the phospho-mimic mutant and WT-ECT2 with itself using a yeast two-hybrid system (Figure 8b ). When T341D was used both as bait and prey (T341D versus T341D, respectively), a strong interaction was observed. In contrast, interaction was barely detectable in WT-ECT2 versus WT-ECT2 or WT-ECT2 versus T341D combination. These observations further support the notion that T341D is in an open form, which increases the accessibility of ECT2-interacting proteins.
Discussion
Cdk1 phosphorylates various proteins and regulates many events during mitosis. In this study, we show that ECT2 is phosphorylated at T341 during G2/M phase most likely by Cdk1 (Figures 1-3) , and this phosphorylation induces a conformational change of ECT2. These results illuminate a new aspect of the regulatory roles of Cdk1 in mitosis.
The introduction of a mutation at T341 to ECT2 changed its activity as detected by SRE reporter gene assays without significantly affecting the subcellular localization of ECT2 (Figures 4 and 7) . Our results suggest that the phosphorylation of ECT2 at T341 by Cyclin B/Cdk1 marginally increases its catalytic activity. ECT2 is located in the nucleus during interphase (Tatsumoto et al., 1999) . Cytoplasmic mislocalization of ECT2 stimulates the activation of Rho-and SRE- mediated transcriptions (Saito et al., 2004) . As the nuclear localization of T341A and T341D mutants was not significantly altered in interphase HEK 293T cells (data not shown), the increase in the activity observed in phospho-mimic mutation was not simply due to the effect of its localization. We also utilized the Rho pulldown assay, but could not detect significant difference between WT-ECT2 and T341 mutants (data not shown). As most ECT2 is in the nucleus, and only the ECT2 molecules in the cytoplasm can activate Rho, a very sensitive method would likely be required to detect the difference. An SRE reporter gene assay using HEK 293T was indeed very sensitive and thus useful for detection of the activity of ECT2. N) and GFPtagged ECT2 derivatives were cotransfected into HEK 293. Cells were lysed 24 h after transfection. GFP-tagged ECT2 derivatives were immunoprecipitated with polyclonal anti-GFP antibody, since monoclonal anti-GFP did not immunoprecipitate GFP-WT-ECT2 efficiently (data not shown). The cell lysates and precipitates were analysed by immunoblotting with anti-flag antibody and monoclonal anti-GFP antibody. ECT2-C was also analysed as a positive control. (b) ECT2-T341D interacts with itself. Interaction was tested by a two-hybrid system with the full length molecules of WT-ECT2 and ECT2-T341D. Each transformant, indicated in the upper box, was grown on SC minus Leu, Ura media (lower, right) or SC minus His media containing 0.5 mM 3-aminotriazole (lower, left).
Expression of dominant-negative ECT2 or RNAi to ECT2 caused multinucleated cells (Figures 5b and 6e) . However, we found that overexpression of WT-ECT2 also induces multinucleated cells in HEK 293T cells (Figure 5b ). It has been reported that the expression of the C-terminal half of ECT2 that has a high level of catalytic activity induces multinucleate cells in AML12 hepatocyte cell lines (Sakata et al., 2000) . Such a paradox is known to exist concerning other signaling molecules. For instance, expression of an activitydefective mutant of MgcRacGAP, which is one of the GTPase-activating proteins (GAP) and involved in cytokinesis, induces multinucleated cells, while overexpression of wild-type MgcRacGAP also inhibits cytokinesis, albeit at a low level (Hirose et al., 2001) . The proper cycling of the GTP-and GDP-bound forms may be important for normal cytokinesis.
Expression of T341 mutants also resulted in multinucleated cells. Since the multinucleation induced by ECT2 siRNA was suppressed by the expression of either the T341A or T341D mutant (Figure 6e ), these mutants should be biologically active. Thus, induction of multinucleated cells by overexpression of either mutant appeared to be due to the high level of activity rather than the dominant-negative effect. The phospho-mimic T341D mutant induced multinucleated cells more efficiently than WT-ECT2 in HEK 293T cells (Figure 5b) , suggesting a higher biological activity of the phosphomimic mutant. We found that ECT2-N bound to the phospho-mimic mutant at T341 more efficiently than WT-ECT2 (Figure 8a ).
Using yeast two-hybrid assays, we also showed that T341D mutants interact with each other, whereas the interaction of WT-ECT2 with either itself or the T341D mutant was not detected in this assay (Figure 8b ). These results suggest that the phosphorylation of ECT2 at T341 opens up its structure by a conformational change (Figure 9 ). Taken together with a marginal increase of the SRE-regulated transcriptional activity of the T341D mutant (Figure 7b ), we propose that this conformational change relieves ECT2 from the auto-inhibition status.
It appears likely that phosphorylation at T341 relieves the interaction between the BRCT and DH domains, which negatively regulates ECT2. Besides the phosphorylation of ECT2, certain binding partners might also contribute to the regulation of ECT2. For example, it has been proposed that some partners of ECT2 that bind to the BRCT domains might positively regulate the function of ECT2 for a completion of cytokinesis (Kim et al., 2005) . Such partners might further activate the phosphorylated form of ECT2 (Figure 9 ). Phosphorylation of ECT2 at T341 might play a role in preparing an open form of ECT2 rather than increasing the activity before anaphase onset. Since the phosphomimic mutant was in an open form (Figure 9 ), the accessibility of ECT2 to other molecules might increase during G2/M phase. Therefore, it is likely that phosphorylation at T341 affects the interaction of ECT2 with such regulators for further regulation. Alternatively, phosphorylation at T341 of ECT2 might be required for the proper function of putative partners to ECT2. The effect of the phosphorylation of ECT2 by Cdk1 shown here might not be the case in Drosophila, since T341 is conserved in human, mouse and Xenopus, but not in Drosophila (Figure 9b ). Drosophila Pebble may have a regulatory mechanism different from human ECT2. Assuming from multiple in vitro phosphorylation sites in ECT2 (Table 1) , additional sites in ECT2 may be phosphorylated in vivo, which may be critical to its catalytic activity. We propose that phosphorylation at T341 by Cyclin B/Cdk1 and subsequent de-phosphorylation could be a trigger for further change(s) of ECT2. We believe our findings provide a new direction for the future investigation of the regulatory mechanism of cytokinesis.
Materials and methods

Cell culture
HeLa or HEK 293T cells were grown in DMEM (Invitrogen, Carlsbad, CA) containing 10% FBS. For double-thymidine block, HeLa cells were arrested with 2 mM thymidine (Sigma, St Louis, MO, USA) for 16 h, and then released in normal growing conditions for 9 h. Cells were then rearrested at G1/S phase with thymidine treatment for 16 h. To prepare mitotic cells, HeLa cells were incubated with 100 ng/ml nocodazole (Sigma) for 16 h and mitotic cells were collected by a mechanical shake-off. For inhibition of Cdk1, cells were incubated with 100 mM roscovitine (A G Scientific, Inc., San Diego, CA, USA) for 30 min after synchronization. For transient transfection, Lipofectamine 2000 reagent (Invitrogen) was used according to the manufacturer's protocol. For immunofluorescence, HEK 293T cells were grown on collagen type I-coated coverslips (BD Bioscience, Bedford, MA, USA).
Plasmid construction
Mutagenesis was achieved by PCR using mutagenizing and outside primers. A set of two complementary mutagenizing primers (sense and antisense) was designed to include the desired changes in their sequence. The following mutagenizing primers were used: for T341A mutation, 5 0 -GCTTTCTCTAA ATGCCCCTAACAGCAATC-GC-3 0 (sense) and 5 0 -GCGAT TGCTGTTA-GGGGCATTTAGAGAAA-GC-3 0 (antisense); for T341D mutation, 5 0 -GCTTTCTCTAAATGAC-CCTAAC AGCAATCGC-3 0 (sense) and 5 0 -GCGATTGCTGTTAGGG TCATTTAGAGAAA-GC-3 0 (antisense). Two segments of the ECT2 cDNA (Acc. No. AY376439) were PCR-amplified independently and then fused in a subsequent overlap extension reaction. Outside primers for ECT2 were as follows: the forward primer which includes an SpeI restriction site (5 0 -GA AGAACTAGTCAGGTTGGTGACATTGGT-C-3 0 ) and the reverse primer which includes an EcoRI restriction site (5 0 -GCA GAATTCTCATA-TCAAATGAGTTGTAGA-3 0 ). The resulting PCR products were subcloned at the SpeI/EcoRI site in a derivative of the pEGFP-C1 expression vector (BD Biosciences Clontech, Palo Alto, CA, USA) containing the WT-ECT2 (full length).
To create siRNA-resistant expression vectors, six mutations were introduced in the region complementary to ECT2 siRNA (see Figure 6b) , using PCR. The mutagenizing primers were as follows: sense: 5 0 -ATTTATAAAGCTTGGGA-GCGCAGAA ACGAACAGCATTTCTAT-3 0 , antisense: 5 0 -ATAGAAATG CTGTTCGTTTCT-GCGCTCCCAAGCTTTATAAAT-3 0 . The DNA sequence of the PCR products was confirmed by DNA sequence analysis.
Preparation of antibody
Anti-ECT2 rabbit antisera (Tatsumoto et al., 1999) were used to prepare an IgG fraction by a protein A-sepharose column (Amersham Phermacia Biotech, Piscataway, NJ, USA). For affinity purification of anti-ECT2 antibodies, maltose-binding protein (MBP) fused to the DH and PH domains of mouse ECT2 were first purified from Escherichia coli using amylose resin (New England Biolabs, Beverly, MA, USA). The resulting MBP-ECT2 was coupled with cyanogen bromideactivated beads (Amersham Pharmacia Biotech) and then used for affinity purification of anti-ECT2 antibody. For immunoprecipitation of ECT2, anti-ECT2 antibody (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used.
In order to analyse phosphorylation of ECT2, a phosphospecific antibody for T341 (pT341) was generated by New England Peptide, Inc. (Gardner, MA, USA). Briefly, a peptide of CKSVSMLSLNpTPNSNRKR was synthesized and used to generate a peptide antibody. The peptide antibody was affinity-purified with a phospho-peptide column, and then subtracted by a nonphospho-peptide column.
The following antibodies were from commercial sources: anti-pTP monoclonal antibody (Cell Signaling Technology, Beverly, MA, USA), anti-b-tubulin (Sigma-Aldrich, St Louis, MO, USA), anti-Flag antibody (M2, Sigma-Aldrich), monoclonal anti-GFP antibody (Clone B34, Covance, Denver, PA, USA), and polyclonal anti-GFP antibody (Molecular Probe, Eugene, OR, USA).
Immunoblotting Cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5), 1% NP-40, 0.1% sodium dodecycl sulfate (SDS), 0.5% deoxychorate, 150 mM NaCl, 2 mM EDTA, 2 mM phenylmethylsulfonyl fluoride, 0.1 mg/ml aprotinin, 0.1 mg/ml leupeptin) at 41C for 30 min. Total cell lysates were clarified by centrifugation at 10 000 g for 15 min at 41C, and then protein concentration was determined using a BCA assay (Pierce, Rockford, IL, USA). Samples were separated and analysed on 8-16% gradient SDS-PAGE gels (Invitrogen), and then transferred to PDVF membranes (Invitrogen). The membrane was blocked with Tris-buffered saline (TBS) containing 3% milk and 0.1% Tween 20. For anti-pTP antibody, TBS containing 2% bovine serum albumin was used for the blocking instead of milk. The membrane was probed with primary antibody, washed with TBS containing 0.1% Tween 20 for 7 min three times, and then probed with horseradish peroxidase-conjugated secondary antibody. Immunoreactive bonds were visualized using Super Signal West-Pico (Pierce) or ECL-plus reagents (Amersham Pharmacia Biotech).
Immunoprecipitation
Antibodies were added to the same amount of cellular proteins from each sample, and incubated for 2 h at 41C. The antigenantibody complex was incubated with protein G-sepharose (Amersham Pharmacia Biotech) for 1 h at 41C. Bound proteins were solubilized in 20 ml of 1 Â SDS buffer and analysed by immunoblotting.
